Terns Pharmaceuticals Inc (NASDAQ: TERN) started the day on Wednesday, with a price increase of 10.65% at $4.26, before settling in for the price of $3.85 at the close. Taking a more long-term approach, TERN posted a 52-week range of $1.87-$11.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 16.38% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 16.38%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -6.16%. This publicly-traded company’s shares outstanding now amounts to $87.30 million, simultaneously with a float of $66.39 million. The organization now has a market capitalization sitting at $372.06 million. At the time of writing, stock’s 50-day Moving Average stood at $3.39, while the 200-day Moving Average is $4.96.
Terns Pharmaceuticals Inc (TERN) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Terns Pharmaceuticals Inc’s current insider ownership accounts for 23.98%, in contrast to 78.77% institutional ownership. According to the most recent insider trade that took place on Jun 27 ’25, this organization’s Chief Financial Officer bought 10,000 shares at the rate of 3.93, making the entire transaction reach 39,283 in total value, affecting insider ownership by 25,000. Preceding that transaction, on Jun 25 ’25, Company’s Chief Executive Officer bought 23,314 for 3.87, making the whole transaction’s value amount to 90,230. This particular insider is now the holder of 47,083 in total.
Terns Pharmaceuticals Inc (TERN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
Terns Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -6.16% and is forecasted to reach -1.21 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -7.00% through the next 5 years, which can be compared against the 16.38% growth it accomplished over the previous five years trading on the market.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
Let’s observe the current performance indicators for Terns Pharmaceuticals Inc (TERN). It’s Quick Ratio in the last reported quarter now stands at 30.89.
In the same vein, TERN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.09, a figure that is expected to reach -0.29 in the next quarter, and analysts are predicting that it will be -1.21 at the market close of one year from today.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
If we take a close look at the recent performances of Terns Pharmaceuticals Inc (NASDAQ: TERN), its last 5-days Average volume was 0.92 million that shows plunge from its year to date volume of 1.19 million. During the previous 9 days, stock’s Stochastic %D was recorded 50.46% While, its Average True Range was 0.33.
Raw Stochastic average of Terns Pharmaceuticals Inc (TERN) in the period of the previous 100 days is set at 82.59%, which indicates a major fall in contrast to 84.52% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 71.00% that was lower than 76.47% volatility it exhibited in the past 100-days period.
